CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: EXOSC6 (ImmuneEditome ID:118460)

1. Gene summary of enriched editing regions for EXOSC6

check button Gene summary
Gene informationGene symbol

EXOSC6

Gene ID

118460

GeneSynonymsEAP4|MTR3|Mtr3p|hMtr3p|p11
GeneCytomap

16q22.1

GeneTypeprotein-coding
GeneDescriptionexosome complex component MTR3|Mtr3 (mRNA transport regulator 3)-homolog|exosome complex exonuclease MTR3|hMtr3|homolog of yeast mRNA transport regulator 3|mRNA transport regulator 3 homolog
GeneModificationdate20230409
UniprotIDQ5RKV6
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr16:70247122-70249962:-ENST00000435634.2ENSG00000223496.2EXOSC6UTR3(A)n,AluSx3,AluSz6,(T)n,AluJb,L1MC5a,AluSzchr16:70247122-70249962:-.alignment


Top

2. Tumor-specific enriched editing regions for EXOSC6


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr16:70247122-70249962:-BRCAEER2.1291e-11image
ENSG00000223496.2,EXOSC6BRCAEAG2.1291e-11image
chr16:70247122-70249962:-COADEER4.6747e-02image
ENSG00000223496.2,EXOSC6COADEAG4.7489e-02image
chr16:70247122-70249962:-KICHEER4.3680e-02image
ENSG00000223496.2,EXOSC6KICHEAG4.3680e-02image
chr16:70247122-70249962:-LUSCEER8.3073e-05image
ENSG00000223496.2,EXOSC6LUSCEAG8.3073e-05image
chr16:70247122-70249962:-THCAEER2.8376e-02image
ENSG00000223496.2,EXOSC6THCAEAG2.8376e-02image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000223496.2,EXOSC6BLCAPathEAG3.1258e-027.1952e-030.1393image
chr16:70247122-70249962:-BLCAPathEER3.3282e-027.7000e-030.1382image
chr16:70247122-70249962:-LUSCPathEER4.0258e-021.7443e-020.1103image
ENSG00000223496.2,EXOSC6LUSCPathEAG4.0258e-021.7443e-020.1103image
ENSG00000223496.2,EXOSC6READPathEAG1.7454e-021.5150e-02-0.2250image
chr16:70247122-70249962:-READPathEER1.7454e-021.5150e-02-0.2250image
ENSG00000223496.2,EXOSC6SKCMPathEAG2.0172e-026.2359e-030.1386image
chr16:70247122-70249962:-SKCMPathEER2.0172e-026.2359e-030.1386image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for EXOSC6


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr16:70247122-70249962:-KICHEERENSG00000138771,SHROOM3-0.55584.1301e-021.3751e-04-0.4726imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr16:70247122-70249962:-KICHEERENSG00000143256,PFDN20.56934.1661e-026.5750e-080.6308imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_FATTY_ACID_METABOLISM
chr16:70247122-70249962:-KICHEERENSG00000183530,PRR14L-0.55954.3776e-024.0703e-04-0.4420imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_PROTEIN_SECRETION
chr16:70247122-70249962:-KICHEERENSG00000177946,CENPBD1-0.53534.8732e-024.9430e-06-0.5515imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_PROTEIN_SECRETION
chr16:70247122-70249962:-DLBCEERENSG00000128731,HERC2-0.59441.6647e-028.6476e-05-0.5625imageNNNAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:70247122-70249962:-DLBCEERENSG00000172270,BSG0.58242.8483e-028.6904e-060.6215imageNNBSGT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:70247122-70249962:-DLBCEERENSG00000153485,TMEM2510.57193.2106e-023.9452e-040.5162imageNNNAPlasma_cellsGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:70247122-70249962:-DLBCEERENSG00000048828,FAM120A-0.55323.8746e-023.5460e-04-0.5197imageNNNAT_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr16:70247122-70249962:-DLBCEERENSG00000187815,ZFP69-0.50824.3887e-023.3441e-04-0.5216imageNNNAT_cells_CD8GSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATION
chr16:70247122-70249962:-DLBCEERENSG00000132326,PER2-0.53764.5565e-028.9405e-04-0.4883imageNNNAB_cells_naiveGSVA_HALLMARK_MITOTIC_SPINDLE

More results



Top

4. Enriched editing regions and immune related splicing for EXOSC6


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
ENSG00000223496.2,EXOSC6
COADEAGIRENSG00000114857.13chr342632600:42633735:42634612:426347000.21073.3777e-026.7879e-100.4131imageNADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RC3H1;RNF219;RTCB;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184NKTRDendritic_cells_activatedGSVA_HALLMARK_ESTROGEN_RESPONSE_LATE
chr16:70247122-70249962:-
TGCTEERESENSG00000198625.8chr1204542788:204542944:204544534:204544684:204546796:204546832-0.26562.1437e-023.8192e-09-0.5114imageNNMDM4Macrophages_M1GSVA_HALLMARK_HYPOXIA
ENSG00000223496.2,EXOSC6
TGCTEAGESENSG00000198625.8chr1204542788:204542944:204544534:204544684:204546796:204546832-0.26561.9988e-023.8192e-09-0.5114imageNADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CBX7;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZFP36;ZNF184MDM4Macrophages_M1GSVA_HALLMARK_HYPOXIA
chr16:70247122-70249962:-
THYMEERMEXENSG00000150991.10chr12124912180:124912583:124912645:124912734:124913039:124913267:124913418:124913774-0.26533.8603e-032.2557e-05-0.4286imageNNNAT_cells_CD8GSVA_HALLMARK_APICAL_SURFACE
chr16:70247122-70249962:-
THYMEERIRENSG00000122386.6chr163115354:3115920:3116426:3116547-0.38354.0690e-032.3732e-05-0.4072imageNNNAT_cells_CD4_naiveGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000223496.2,EXOSC6
THYMEAGMEXENSG00000001036.9chr6143502354:143502565:143503912:143504074:143504166:143504252:143507236:1435074240.31243.8200e-025.8203e-070.4775imageNADAR;AIFM1;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX54;DGCR8;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM27;RBM47;RNF219;SF3A3;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_PROTEIN_SECRETION
chr16:70247122-70249962:-
THYMEERIRENSG00000083799.13chr1650786838:50786946:50787785:507878520.35677.7411e-031.0546e-100.5876imageNNCYLDT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
ENSG00000223496.2,EXOSC6
THYMEAGIRENSG00000083799.13chr1650786838:50786946:50787785:507878520.35678.1066e-031.0546e-100.5876imageNADAR;BCCIP;BUD13;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LIN28;LIN28B;LSM11;MBNL2;MOV10;MSI2;NONO;NOP56;NOP58;NUMA1;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM47;RC3H1;SAFB2;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184CYLDT_cells_follicular_helperGSVA_HALLMARK_PROTEIN_SECRETION
chr16:70247122-70249962:-
THYMEERMEXENSG00000150991.10chr12124912355:124912583:124912645:124912734:124913039:124913092:124913418:124913440-0.28053.8793e-031.8185e-05-0.4329imageNNNADendritic_cells_restingGSVA_HALLMARK_APICAL_SURFACE
chr16:70247122-70249962:-
THYMEERMEXENSG00000150991.10chr12124912506:124912583:124912636:124912734:124913039:124913267:124913418:124913774-0.26523.8866e-032.9962e-05-0.4227imageNNNAT_cells_CD8GSVA_HALLMARK_APICAL_SURFACE

More results



Top

5. Enriched editing regions and immune infiltration for EXOSC6


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr16:70247122-70249962:-BRCAEERMacrophages_M04.7684e-02-0.0612image
ENSG00000223496.2,EXOSC6BRCAEAGMacrophages_M04.7684e-02-0.0612image
chr16:70247122-70249962:-CESCEEREosinophils2.1912e-02-0.1387image
ENSG00000223496.2,EXOSC6CESCEAGEosinophils2.1912e-02-0.1387image
chr16:70247122-70249962:-CHOLEERPlasma_cells3.3204e-020.3661image
ENSG00000223496.2,EXOSC6CHOLEAGPlasma_cells3.3204e-020.3661image
chr16:70247122-70249962:-COADEERDendritic_cells_resting2.3940e-02-0.1437image
ENSG00000223496.2,EXOSC6COADEAGDendritic_cells_resting2.2304e-02-0.1454image
chr16:70247122-70249962:-DLBCEERPlasma_cells5.2673e-030.4181image
ENSG00000223496.2,EXOSC6DLBCEAGPlasma_cells5.2673e-030.4181image
chr16:70247122-70249962:-ESCAEERMonocytes8.0038e-03-0.2083image
ENSG00000223496.2,EXOSC6ESCAEAGMonocytes8.0038e-03-0.2083image
chr16:70247122-70249962:-GBMEERT_cells_CD4_memory_resting7.4512e-040.2608image
ENSG00000223496.2,EXOSC6GBMEAGT_cells_CD4_memory_resting7.1740e-040.2615image
chr16:70247122-70249962:-HNSCEERB_cells_naive1.8026e-02-0.1115image
ENSG00000223496.2,EXOSC6HNSCEAGB_cells_naive2.0088e-02-0.1096image
chr16:70247122-70249962:-KICHEERT_cells_CD4_memory_activated8.3480e-030.3376image
ENSG00000223496.2,EXOSC6KICHEAGT_cells_CD4_memory_activated8.3480e-030.3376image
chr16:70247122-70249962:-KIRCEERPlasma_cells3.6403e-030.1488image
ENSG00000223496.2,EXOSC6KIRCEAGPlasma_cells3.5952e-030.1490image
chr16:70247122-70249962:-KIRPEERT_cells_gamma_delta2.0157e-02-0.1424image
ENSG00000223496.2,EXOSC6KIRPEAGT_cells_gamma_delta2.0281e-02-0.1423image
chr16:70247122-70249962:-LGGEERMacrophages_M01.9670e-02-0.1014image
ENSG00000223496.2,EXOSC6LGGEAGMacrophages_M01.9670e-02-0.1014image
chr16:70247122-70249962:-LIHCEERNK_cells_resting1.1042e-020.1498image
ENSG00000223496.2,EXOSC6LIHCEAGNK_cells_resting1.0876e-020.1501image
chr16:70247122-70249962:-LUSCEERDendritic_cells_resting3.8044e-03-0.1337image
ENSG00000223496.2,EXOSC6LUSCEAGDendritic_cells_resting3.8044e-03-0.1337image
chr16:70247122-70249962:-MESOEERDendritic_cells_activated1.6443e-030.3507image
ENSG00000223496.2,EXOSC6MESOEAGDendritic_cells_activated1.6443e-030.3507image
chr16:70247122-70249962:-OVEERT_cells_regulatory_(Tregs)5.0738e-040.2040image
ENSG00000223496.2,EXOSC6OVEAGT_cells_regulatory_(Tregs)1.3813e-030.1879image
chr16:70247122-70249962:-PCPGEERMast_cells_activated1.6994e-020.1772image
ENSG00000223496.2,EXOSC6PCPGEAGMast_cells_activated1.6994e-020.1772image
chr16:70247122-70249962:-PRADEERT_cells_regulatory_(Tregs)4.4123e-020.0918image
ENSG00000223496.2,EXOSC6PRADEAGT_cells_regulatory_(Tregs)4.4123e-020.0918image
chr16:70247122-70249962:-READEERDendritic_cells_resting2.2449e-02-0.2445image
ENSG00000223496.2,EXOSC6READEAGDendritic_cells_resting2.2449e-02-0.2445image
chr16:70247122-70249962:-SARCEEREosinophils8.9956e-030.1690image
ENSG00000223496.2,EXOSC6SARCEAGEosinophils8.9956e-030.1690image
chr16:70247122-70249962:-SKCMEERT_cells_CD81.2836e-030.1520image
ENSG00000223496.2,EXOSC6SKCMEAGT_cells_CD81.2836e-030.1520image
chr16:70247122-70249962:-STADEERT_cells_CD87.0855e-030.1415image
ENSG00000223496.2,EXOSC6STADEAGT_cells_CD86.7715e-030.1423image
chr16:70247122-70249962:-TGCTEERT_cells_CD4_naive4.1169e-030.2369image
ENSG00000223496.2,EXOSC6TGCTEAGT_cells_CD4_naive4.1169e-030.2369image
chr16:70247122-70249962:-THCAEERNK_cells_activated5.1536e-030.1259image
ENSG00000223496.2,EXOSC6THCAEAGNK_cells_activated5.1536e-030.1259image
chr16:70247122-70249962:-THYMEERT_cells_follicular_helper2.2561e-020.2135image
ENSG00000223496.2,EXOSC6THYMEAGT_cells_follicular_helper2.2561e-020.2135image
chr16:70247122-70249962:-UCSEERNeutrophils3.4187e-020.2888image
ENSG00000223496.2,EXOSC6UCSEAGNeutrophils3.4187e-020.2888image
ENSG00000223496.2,EXOSC6UVMEAGB_cells_naive3.6840e-030.3664image


Top

6. Enriched editing regions and immune gene sets for EXOSC6


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr16:70247122-70249962:-LUADEER1.4087e-020.11522.5604e-020.10481.3591e-020.11581.6686e-030.1471image
ENSG00000223496.2,EXOSC6LUADEAG1.4087e-020.11522.5604e-020.10481.3591e-020.11581.6686e-030.1471image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
chr16:70247122-70249962:-ACCGSVA_HALLMARK_MITOTIC_SPINDLEEER6.9389e-03-0.3073image
ENSG00000223496.2,EXOSC6ACCGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.9389e-03-0.3073image
ENSG00000223496.2,EXOSC6BLCAGSVA_HALLMARK_HYPOXIAEAG1.6756e-020.1241image
chr16:70247122-70249962:-BLCAGSVA_HALLMARK_HYPOXIAEER1.7288e-020.1235image
ENSG00000223496.2,EXOSC6BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.2684e-050.1281image
chr16:70247122-70249962:-BRCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.2684e-050.1281image
chr16:70247122-70249962:-CESCGSVA_HALLMARK_COMPLEMENTEER2.8823e-030.1797image
ENSG00000223496.2,EXOSC6CESCGSVA_HALLMARK_COMPLEMENTEAG2.8823e-030.1797image
chr16:70247122-70249962:-CHOLGSVA_HALLMARK_PANCREAS_BETA_CELLSEER2.7170e-020.3788image
ENSG00000223496.2,EXOSC6CHOLGSVA_HALLMARK_PANCREAS_BETA_CELLSEAG2.7170e-020.3788image
ENSG00000223496.2,EXOSC6COADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEAG6.2872e-030.1734image
chr16:70247122-70249962:-COADGSVA_HALLMARK_ALLOGRAFT_REJECTIONEER5.8498e-030.1749image
chr16:70247122-70249962:-DLBCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEER5.9102e-03-0.4130image
ENSG00000223496.2,EXOSC6DLBCGSVA_HALLMARK_HEDGEHOG_SIGNALINGEAG5.9102e-03-0.4130image
ENSG00000223496.2,EXOSC6ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.6056e-040.2932image
chr16:70247122-70249962:-ESCAGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.6056e-040.2932image
ENSG00000223496.2,EXOSC6GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEAG9.8204e-050.2994image
chr16:70247122-70249962:-GBMGSVA_HALLMARK_BILE_ACID_METABOLISMEER9.2622e-050.3005image
chr16:70247122-70249962:-HNSCGSVA_HALLMARK_SPERMATOGENESISEER1.3757e-03-0.1504image
ENSG00000223496.2,EXOSC6HNSCGSVA_HALLMARK_SPERMATOGENESISEAG1.7914e-03-0.1468image
ENSG00000223496.2,EXOSC6KICHGSVA_HALLMARK_APICAL_SURFACEEAG7.1750e-03-0.3437image
chr16:70247122-70249962:-KICHGSVA_HALLMARK_APICAL_SURFACEEER7.1750e-03-0.3437image
chr16:70247122-70249962:-KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER2.0767e-030.1575image
ENSG00000223496.2,EXOSC6KIRCGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG2.0685e-030.1575image
chr16:70247122-70249962:-KIRPGSVA_HALLMARK_COAGULATIONEER2.1836e-030.1871image
ENSG00000223496.2,EXOSC6KIRPGSVA_HALLMARK_COAGULATIONEAG2.1731e-030.1872image
ENSG00000223496.2,EXOSC6LGGGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.2197e-11-0.2891image
chr16:70247122-70249962:-LGGGSVA_HALLMARK_MITOTIC_SPINDLEEER1.2197e-11-0.2891image
ENSG00000223496.2,EXOSC6LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEAG1.6613e-030.1848image
chr16:70247122-70249962:-LIHCGSVA_HALLMARK_MITOTIC_SPINDLEEER1.7612e-030.1839image
ENSG00000223496.2,EXOSC6LUADGSVA_HALLMARK_UV_RESPONSE_UPEAG2.0375e-040.1735image
chr16:70247122-70249962:-LUADGSVA_HALLMARK_UV_RESPONSE_UPEER2.0375e-040.1735image
ENSG00000223496.2,EXOSC6LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.2215e-040.1559image
chr16:70247122-70249962:-LUSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.2215e-040.1559image
ENSG00000223496.2,EXOSC6OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.5692e-070.2985image
chr16:70247122-70249962:-OVGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER9.6323e-080.3085image
ENSG00000223496.2,EXOSC6PAADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEAG3.5958e-02-0.1670image
chr16:70247122-70249962:-PAADGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER3.5958e-02-0.1670image
ENSG00000223496.2,EXOSC6PRADGSVA_HALLMARK_MITOTIC_SPINDLEEAG6.0777e-08-0.2439image
chr16:70247122-70249962:-PRADGSVA_HALLMARK_MITOTIC_SPINDLEEER6.0777e-08-0.2439image
ENSG00000223496.2,EXOSC6READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.5386e-030.2846image
chr16:70247122-70249962:-READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER7.5386e-030.2846image
chr16:70247122-70249962:-SARCGSVA_HALLMARK_KRAS_SIGNALING_DNEER1.7915e-03-0.2014image
ENSG00000223496.2,EXOSC6SARCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG1.7915e-03-0.2014image
chr16:70247122-70249962:-SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEER7.7306e-05-0.1861image
ENSG00000223496.2,EXOSC6SKCMGSVA_HALLMARK_MITOTIC_SPINDLEEAG7.7306e-05-0.1861image
ENSG00000223496.2,EXOSC6STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG2.8331e-050.2184image
chr16:70247122-70249962:-STADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.8300e-050.2234image
ENSG00000223496.2,EXOSC6TGCTGSVA_HALLMARK_UV_RESPONSE_UPEAG1.1496e-020.2094image
chr16:70247122-70249962:-TGCTGSVA_HALLMARK_UV_RESPONSE_UPEER1.1496e-020.2094image
chr16:70247122-70249962:-THCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.5231e-060.2148image
ENSG00000223496.2,EXOSC6THCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG1.5231e-060.2148image
ENSG00000223496.2,EXOSC6THYMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEAG6.5957e-050.3648image
chr16:70247122-70249962:-THYMGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER6.5957e-050.3648image
ENSG00000223496.2,EXOSC6UCECGSVA_HALLMARK_APICAL_SURFACEEAG1.9103e-020.1875image
chr16:70247122-70249962:-UCECGSVA_HALLMARK_APICAL_SURFACEEER1.8725e-020.1881image
chr16:70247122-70249962:-UCSGSVA_HALLMARK_MYOGENESISEER1.1518e-03-0.4306image
ENSG00000223496.2,EXOSC6UCSGSVA_HALLMARK_MYOGENESISEAG1.1518e-03-0.4306image
ENSG00000223496.2,EXOSC6UVMGSVA_HALLMARK_PROTEIN_SECRETIONEAG7.6942e-03-0.3381image


Top

7. Enriched editing regions and drugs for EXOSC6


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
chr16:70247122-70249962:-ACCAS601245EER1.1645e-020.2880image
ENSG00000223496.2,EXOSC6ACCAS601245EAG1.1645e-020.2880image
chr16:70247122-70249962:-BLCABleomycinEER2.1134e-03-0.1591image
ENSG00000223496.2,EXOSC6BLCABleomycinEAG1.8979e-03-0.1607image
chr16:70247122-70249962:-BRCAAMG.706EER4.5488e-04-0.1082image
ENSG00000223496.2,EXOSC6BRCAAMG.706EAG4.5488e-04-0.1082image
ENSG00000223496.2,EXOSC6CESCBosutinibEAG3.2597e-03-0.1775image
chr16:70247122-70249962:-CESCBosutinibEER3.2597e-03-0.1775image
chr16:70247122-70249962:-CHOLCGP.60474EER3.8492e-02-0.3565image
ENSG00000223496.2,EXOSC6CHOLCGP.60474EAG3.8492e-02-0.3565image
ENSG00000223496.2,EXOSC6COADABT.263EAG3.9984e-03-0.1825image
chr16:70247122-70249962:-COADABT.263EER5.3808e-03-0.1766image
chr16:70247122-70249962:-DLBCAG.014699EER2.0173e-020.3532image
ENSG00000223496.2,EXOSC6DLBCAG.014699EAG2.0173e-020.3532image
ENSG00000223496.2,EXOSC6ESCACCT007093EAG7.6844e-030.2094image
chr16:70247122-70249962:-ESCACCT007093EER7.6844e-030.2094image
chr16:70247122-70249962:-GBMLapatinibEER9.4189e-05-0.3002image
ENSG00000223496.2,EXOSC6GBMLapatinibEAG1.3541e-04-0.2937image
chr16:70247122-70249962:-HNSCMetforminEER5.8071e-05-0.1884image
ENSG00000223496.2,EXOSC6HNSCMetforminEAG9.2575e-05-0.1832image
ENSG00000223496.2,EXOSC6KICHAZD.2281EAG1.3294e-06-0.5779image
chr16:70247122-70249962:-KICHAZD.2281EER1.3294e-06-0.5779image
ENSG00000223496.2,EXOSC6KIRCCI.1040EAG2.4366e-04-0.1872image
chr16:70247122-70249962:-KIRCCI.1040EER2.3969e-04-0.1874image
ENSG00000223496.2,EXOSC6KIRPBAY.61.3606EAG1.2753e-020.1525image
chr16:70247122-70249962:-KIRPBAY.61.3606EER1.2723e-020.1526image
ENSG00000223496.2,EXOSC6LAMLBIRB.0796EAG1.0026e-020.2392image
ENSG00000223496.2,EXOSC6LGGBAY.61.3606EAG4.8853e-180.3642image
chr16:70247122-70249962:-LGGBAY.61.3606EER4.8853e-180.3642image
chr16:70247122-70249962:-LIHCDasatinibEER1.7985e-030.1961image
ENSG00000223496.2,EXOSC6LIHCDasatinibEAG1.7985e-030.1961image
ENSG00000223496.2,EXOSC6LUADGNF.2EAG6.0159e-04-0.1604image
chr16:70247122-70249962:-LUADGNF.2EER6.0159e-04-0.1604image
chr16:70247122-70249962:-LUSCCEP.701EER1.0429e-03-0.1512image
ENSG00000223496.2,EXOSC6LUSCCEP.701EAG1.0429e-03-0.1512image
chr16:70247122-70249962:-MESODasatinibEER4.2305e-02-0.2305image
ENSG00000223496.2,EXOSC6MESODasatinibEAG4.2305e-02-0.2305image
chr16:70247122-70249962:-OVJW.7.52.1EER9.4223e-05-0.2285image
ENSG00000223496.2,EXOSC6OVJW.7.52.1EAG1.0351e-04-0.2271image
chr16:70247122-70249962:-PCPGLapatinibEER3.2383e-02-0.1591image
ENSG00000223496.2,EXOSC6PCPGLapatinibEAG3.2383e-02-0.1591image
ENSG00000223496.2,EXOSC6PRADAZ628EAG1.3001e-08-0.2577image
chr16:70247122-70249962:-PRADAZ628EER1.3001e-08-0.2577image
ENSG00000223496.2,EXOSC6SARCGSK.650394EAG8.0870e-030.1713image
chr16:70247122-70249962:-SARCGSK.650394EER8.0870e-030.1713image
chr16:70247122-70249962:-SKCMGNF.2EER2.3868e-08-0.2604image
ENSG00000223496.2,EXOSC6SKCMGNF.2EAG2.3868e-08-0.2604image
chr16:70247122-70249962:-STADAZ628EER1.6811e-05-0.2244image
ENSG00000223496.2,EXOSC6STADAZ628EAG2.6783e-05-0.2191image
ENSG00000223496.2,EXOSC6TGCTEHT.1864EAG6.9831e-030.2231image
chr16:70247122-70249962:-TGCTEHT.1864EER6.9831e-030.2231image
ENSG00000223496.2,EXOSC6THCABMS.536924EAG7.8303e-11-0.2883image
chr16:70247122-70249962:-THCABMS.536924EER7.8303e-11-0.2883image
ENSG00000223496.2,EXOSC6THYMAKT.inhibitor.VIIIEAG1.2301e-030.2990image
chr16:70247122-70249962:-THYMAKT.inhibitor.VIIIEER1.2301e-030.2990image
ENSG00000223496.2,EXOSC6UCSGW.441756EAG1.5282e-04-0.4929image
chr16:70247122-70249962:-UCSGW.441756EER1.5282e-04-0.4929image
ENSG00000223496.2,EXOSC6UVMBIRB.0796EAG1.0468e-020.3255image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType